본문 바로가기
KERD
논문KCI 등재

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Mindie H. Nguyen|Ramsey Cheung|Linda Henry|Yee Hui Yeo|Michael H. Le|Biyao Zou|Scott Barnet
대한간학회 (The korean Association for the Study of the Liver)|2022.10|Clinical and Molecular Hepatology|제28권 제4호|pp. 841-850

0

조회

0

다운로드

16

인용

0

참고문헌

키워드

SmokingWomenMetabolic syndromeTrends

초록

Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040. Methods: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality. Results: The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85). Conclusions: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease.

Abstract

Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040. Methods: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality. Results: The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85). Conclusions: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease.

참고문헌 (43)

  1. Cusi K, "American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings : co-sponsored by the American Association for the Study of Liver Diseases(AASLD)", Endocr Pract, 28, pp.528~562 (2022)
  2. Michael H. Le, "2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis", Clinical Gastroenterology and Hepatology, 20(12), pp.2809~2817.e28 (2022), Elsevier BV[DOI]
  3. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  4. Golabi P, "Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa : data from global burden of disease 2009-2019", J Hepatol, 75, pp.795~809 (2021)
  5. Li J, "Meta-analysis : global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021", Aliment Pharmacol Ther, 56, pp.396~406 (2022)
  6. Younossi ZM, "Fatty liver through the ages : nonalcoholic steatohepatitis", Endocr Pract, 28, pp.204~213 (2022)
  7. Manne V, "Pathophysiology of nonalcoholic fatty liver disease", nonalcoholic steatohepatitis, 2018, pp.22, 23~37
  8. Younossi ZM, "The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe", Hepatology, 64, pp.1577~1586 (2016)
  9. Paik JM, "The growing burden of disability related to chronic liver disease in the United States : data from the Global Burden of Disease Study 2007-2017", Hepatol Commun, 5, pp.749~759 (2021)
  10. Paik JM, "The growing burden of disability related to nonalcoholic fatty liver disease : data from the Global Burden of Disease 2007-2017", Hepatol Commun, 4, pp.1769~1780 (2020)
  11. Younossi ZM, "Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis", Hepatol Commun, 5, pp.1201~1211 (2021)
  12. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
  13. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
  14. Alswat K, "Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030", Saudi J Gastroenterol, 24, pp.211~219 (2018)
  15. Goossens N, "Nonalcoholic fatty liver disease burden-Switzerland 2018-2030", Swiss Med Wkly, 149, pp.w20152~ (2019)
  16. Swain MG, "Burden of nonalcoholic fatty liver disease in Canada, 2019-2030 : a modelling study", CMAJ Open, 8, pp.E429~E436 (2020)
  17. Adams LA, "Nonalcoholic fatty liver disease burden : Australia, 2019-2030", J Gastroenterol Hepatol, 35, pp.1628~1635 (2020)
  18. Wu Y, "The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product : a meta-analysis", Hepatol Int, 14, pp.259~269 (2020)
  19. DelSole T, "A fundamental limitation of Markov models", J Atmos Sci, 57, pp.2158~2168 (2000)
  20. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
  21. Golabi P, "Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality", Clin Diabetes, 37, pp.65~72 (2019)
  22. Younossi ZM, "Nonalcoholic fatty liver disease in lean individuals in the United States", Medicine(Baltimore), 91, pp.319~327 (2012)
  23. Riazi K, "The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
  24. Golabi P, "Liver transplantation (LT) for cryptogenic cirrhosis (CC)and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the scientific registry of transplant recipients (SRTR): 1994 to 2016", Medicine(Baltimore), 97, pp.e11518~ (2018)
  25. Younossi ZM, "Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States", Clin Gastroenterol Hepatol, 19, pp.580~589 (2021)
  26. Le MH, "Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016", J Intern Med, 287, pp.711~722 (2020)
  27. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755 (2019)
  28. Younossi ZM, "A global survey of physicians knowledge about nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.e1456~e1468 (2022)
  29. Alqahtani SA, "Poor awareness of liver disease among adults with NAFLD in the United States", Hepatol Commun, 5, pp.1833~1847 (2021)
  30. Bush H, "Pediatric non-alcoholic fatty liver disease", Children(Basel), 4, pp.48~ (2017)
  31. Arshad T, "Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016", Hepatol Commun, 5, pp.1676~1688 (2021)
  32. Arshad T, "Prevalence of nonalcoholic fatty liver disease in the female population", Hepatol Commun, 3, pp.74~83 (2018)
  33. Wang J, "Associations between reproductive and hormone-related factors and risk of nonalcoholic fatty liver disease in a multiethnic population", Clin Gastroenterol Hepatol, 19, pp.1258~1266 (2021)
  34. Noureddin M, "NASH leading cause of liver transplant in women : updated analysis of indications for liver transplant and ethnic and gender variances", Am J Gastroenterol, 113, pp.1649~1659 (2018)
  35. Stefan N, "A global view of the interplay between nonalcoholic fatty liver disease and diabetes", Lancet Diabetes Endocrinol, 10, pp.284~296 (2022)
  36. Khan RS, "Modulation of insulin resistance in nonalcoholic fatty liver disease", Hepatology, 70, pp.711~724 (2019)
  37. Golabi P, "Mortality of NAFLD according to the body composition and presence of metabolic abnormalities", Hepatol Commun, 4, pp.1136~1148 (2020)
  38. "Current smokers"[URL]
  39. Xu Gao, "Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States", Journal of Hepatology, 78(1), pp.16~27 (2023), Elsevier BV[DOI]
  40. Yeo YH, "Trends of cirrhosis-related mortality in the United States during the COVID-19pandemic : a cohort study", J Clin Trans Hepatol (2022)[DOI]
  41. Cheng Han Ng, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name", Clinical and Molecular Hepatology, 28(4), pp.790~801 (2022), 대한간학회
  42. Naoshi Odagiri, "Anti-fibrotic treatments for chronic liver diseases: The present and the future", Clinical and Molecular Hepatology, 27(3), pp.413~424 (2021), 대한간학회[DOI]
  43. Han Ah Lee, "Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases", Clinical and Molecular Hepatology, 28(3), pp.425~472 (2022), 대한간학회

관련 논문AI추천

Global incidence and prevalence of nonalcoholic fatty liver diseaseCheng Han Ng, Daniel Q. Huang, Darren JH Tan, Eunice Tan, Ju Dong Yang, Kai En Chan, Margaret LP Teng, Mark D. Muthiah, Wen Hui Lim대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Recent Epidemiology of Nonalcoholic Fatty Liver DiseaseAhmed Aijaz, Kim Donghee, Murag Soumya거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제2호Global incidence of adverse clinical events in nonalcoholic fatty liver disease: A systematic review and meta-analysisChristopher D. Stave, David M. Le, Fanpu Ji, Hansen Dang, KeeSeok Lee, Michael H. Le, Mindie H. Nguyen, Ramsey Cheung, Takanori Ito, Thomas C. Baez, Vy H. Nguyen, Yee Hui Yeo, Yuankai Wu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제2호Epidemiology of metabolic dysfunction-associated steatotic liver diseaseLinda Henry, Markos Kalligeros, Zobair M. Younossi대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in nameCheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호Non-alcoholic fatty liver disease: Definition and subtypes김문영, 백순구, Seul Ki Han대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호

이 간행물의 다른 논문 (24건)

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinomaNational Cancer Center (NCC) Korea, Korean Liver Cancer Association (KLCA)pp. 583-705The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathologyJong-Hoon Kim, Youngseok Leepp. 706-724Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative reviewGiovanni Targher, Ming-Hua Zheng, Jing Xu, Lei Miao, Christopher D Byrnepp. 725-738Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive reviewJong Man Kim, Sang Jin Kimpp. 739-753Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncologyHyun-Jong Jang, Sung Hak Leepp. 754-772
원문 보기